{"id":"W2586861001","doi":"10.1097/01.mib.0000442971.65229.5b","title":"P-145 WELCOME 54-week Open-label Extension","year":2014,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Certolizumab pegol; Infliximab; Open label; Adverse effect; Open label study; Internal medicine; Bristol-Myers; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003342994,0.000662555,0.001250054,0.0002814882,0.0003753489,0.0007063746,0.0005915781,0.001402041,0.03366235],"category_scores_gemma":[0.003657333,0.00033085,0.001392849,0.0002366955,0.0004689159,0.0007205647,0.0007311539,0.002948698,0.005382959],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003692149,"about_ca_system_score_gemma":0.001047027,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003551768,"about_ca_topic_score_gemma":0.000711995,"domain_scores_codex":[0.9985766,0.000753539,0.00007699038,0.0002166613,0.0001844645,0.0001916045],"domain_scores_gemma":[0.996877,0.0008191022,0.0006639038,0.000643055,0.0003382105,0.000658732],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7283143,0.02522297,0.003494984,0.001217759,0.0006156106,0.000243932,0.0001617701,0.000912837,0.02594345,0.0008595005,0.03472935,0.1782835],"study_design_scores_gemma":[0.5298259,0.3254875,0.02820518,0.0004089398,0.0006229911,0.0005469312,0.00006730582,0.001447874,0.010359,0.0008467396,0.1020994,0.00008216634],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9037816,0.00793262,0.008348236,0.002659927,0.002502132,0.01508386,0.02115676,0.001303119,0.03723175],"genre_scores_gemma":[0.8959364,0.002328587,0.008147781,0.002894249,0.001406515,0.02476932,0.01663202,0.0002726273,0.04761246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03366235,"threshold_uncertainty_score":0.1126118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01647473866427141,"score_gpt":0.2605411443937827,"score_spread":0.2440664057295113,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}